Département de Génétique Médicale, Unité INSERM U933, Hôpital Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France.
Département de Génétique Médicale, Unité INSERM U933, Hôpital Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France.
Fertil Steril. 2022 Apr;117(4):843-853. doi: 10.1016/j.fertnstert.2021.12.023. Epub 2022 Jan 31.
To study the diagnostic yield, including variants in genes yet to be incriminated, of whole exome sequencing (WES) in familial cases of premature ovarian insufficiency (POI).
Cross-sectional study.
Endocrinology and reproductive medicine teaching hospital departments.
Familial POI cases were recruited as part of a nationwide multicentric cohort. A total of 36 index cases in 36 different families were studied. Fifty-two relatives were available, including 25 with POI and 27 affected who were nonaffected. Karyotype analysis, FMR1 screening, single nucleotide polymorphism array analysis, and WES were performed in all subjects.
None.
The primary outcome was a molecular etiology, as diagnosed by karyotype, FMR1 screening, single nucleotide polymorphism array, and WES.
A likely molecular etiology (pathogenic or likely pathogenic variant) was identified in 18 of 36 index cases (50% diagnostic yield). In 12 families, we found a pathogenic or likely pathogenic variant in a gene previously incriminated in POI, and in 6 families, we found a pathogenic or likely pathogenic variant in new candidate genes. Most of the variants identified were located in genes involved in cell division and meiosis (n = 11) or DNA repair (n = 4).
The genetic etiologic diagnosis in POI allows for genetic familial counseling, anticipated pregnancy planning, and ovarian tissue preservation or oocyte preservation. Identifying new genes may lead to future development of therapeutics in reproduction based on disrupted molecular pathways.
NCT 01177891.
研究全外显子组测序(WES)在家族性早发性卵巢功能不全(POI)病例中的诊断产量,包括尚未被牵连的基因变异。
横断面研究。
内分泌学和生殖医学教学医院科室。
家族性 POI 病例是作为全国多中心队列的一部分招募的。共研究了 36 个不同家庭的 36 个指数病例。共有 52 名亲属可供研究,其中 25 名患有 POI,27 名受影响但未受影响。所有受试者均进行了核型分析、FMR1 筛查、单核苷酸多态性微阵列分析和 WES。
无。
主要结局是通过核型分析、FMR1 筛查、单核苷酸多态性微阵列和 WES 诊断的分子病因。
在 36 个指数病例中有 18 个(50%的诊断产量)确定了可能的分子病因(致病或可能致病的变异)。在 12 个家庭中,我们发现了一个先前与 POI 有关的基因中的致病或可能致病的变异,在 6 个家庭中,我们发现了一个新的候选基因中的致病或可能致病的变异。大多数鉴定的变异位于参与细胞分裂和减数分裂的基因(n=11)或 DNA 修复基因(n=4)。
POI 的遗传病因诊断可进行遗传家族咨询、预期妊娠计划以及卵巢组织保存或卵母细胞保存。鉴定新基因可能会导致未来基于受损分子途径的生殖治疗的发展。
NCT01177891。